Sanofi-GSK Covid-19 vaccine candidate shows 95% to 100% seroconversion
The vaccine showed immune responses consistent with those measured in people recovered from Covid-19, in all adult age…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
18 May 21
The vaccine showed immune responses consistent with those measured in people recovered from Covid-19, in all adult age…
10 May 21
The transaction will provide the combined entity with about $250m to fund its decentralised trial technology platform, expand…
21 Apr 21
Avigan is an anti-influenza drug, approved for domestic use in March 2014, for the treatment of new or…
16 Apr 21
The business combination would add highly complementary services that further enhance Thermo Fisher’s value proposition for pharma and…
05 Apr 21
BNT162b2 was 100% effective against severe Covid-19, as defined by the CDC, and 95.3% effective against severe Covid-19,…
26 Mar 21
The Phase 1/2/3 trial will evaluate two-dose mRNA vaccine BNT162b2, administered 21 days apart, in three age groups
25 Mar 21
The analysis confirmed that the AZD1222 vaccine is 76% effective against symptomatic Covid-19, and 100% against severe disease…
23 Mar 21
AZD1222 showed 79% vaccine efficacy in preventing symptomatic Covid-19 and 100% efficacy against severe Covid-19 and hospitalisation
12 Mar 21
The MoH analysis showed at least 97% vaccine effectiveness against symptomatic Covid-19 cases, and 94% against asymptomatic SARS-CoV-2…
26 Feb 21
The Phase 1/2/3 trial evaluates the safety and tolerability of a third dose of BNT162b2 and its effectiveness…